| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/21/2002 | DE10045047A1 Arzneimittel enthaltend aktiviertes Antithrombin III Medicines containing activated antithrombin III |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2687476A1 N-phenyl-2-pyrimidine-amine derivatives |
| 03/21/2002 | CA2422828A1 Novel tumor-associated marker |
| 03/21/2002 | CA2422814A1 Cripto mutant and uses thereof |
| 03/21/2002 | CA2422603A1 Vectors for molecule delivery to cd11b expressing cells |
| 03/21/2002 | CA2422597A1 T cell receptor transfer into a candidate effector cell or a precursor thereof |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422575A1 Composition comprising immunogenic microparticles |
| 03/21/2002 | CA2422454A1 Compositions and methods for inducing specific cytolytic t cell responses |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422278A1 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | CA2422229A1 Calcium binding proteins |
| 03/21/2002 | CA2422163A1 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422060A1 Compositions comprising mixtures of human cytokines and methods of producing the same |
| 03/21/2002 | CA2422053A1 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421751A1 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 03/21/2002 | CA2421652A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421585A1 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2421234A1 Interferon-alpha induced gene |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/20/2002 | EP1188832A1 A delivery method for the tumor specific apoptosis inducing activity of apoptin |
| 03/20/2002 | EP1188827A1 Processes for the fusion of dendritic cells with tumor cells and media for such processes |
| 03/20/2002 | EP1188825A1 T cell receptor transfer into a candidate effector cell or a precursor thereof |
| 03/20/2002 | EP1188768A2 LHRH antagonist peptides |
| 03/20/2002 | EP1188765A1 Mechanism oriented inhibitors of dipeptidyl peptidase I |
| 03/20/2002 | EP1188446A1 Proteinaceous vectors for molecule delivery to CD11b expressing cells |
| 03/20/2002 | EP1188439A2 Cell differentiation induction with mevalonate and mevalonolactone derivatives |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1188057A2 Incorporation and appliations of biomolecular interactions within a carrier |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187929A2 Novel liposomal vector complexes and their use in gene therapy |
| 03/20/2002 | EP1187924A1 Substrate trapping protein tyrosine phosphatases |
| 03/20/2002 | EP1187919A2 Recombinant adenoviruses for the sodium/iodide symporter (nis) |
| 03/20/2002 | EP1187918A1 Tek antagonists |
| 03/20/2002 | EP1187915A2 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 03/20/2002 | EP1187913A1 Screening method for peptides |
| 03/20/2002 | EP1187908A1 42 human secreted proteins |
| 03/20/2002 | EP1187849A1 Meth1 and meth2 polynucleotides and polypeptides |
| 03/20/2002 | EP1187846A2 11beta long-chain substituted estratrienes, method for their production, pharmaceutical preparations containing said 11beta long-chain substituted estratrienes, and their use for producing medicaments |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187842A1 Human tumor necrosis factor receptor tr10 |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187826A1 Heterocyclic derivatives useful as anticancer agents |
| 03/20/2002 | EP1187816A1 5-cyano-2-aminopyrimidine derivatives |
| 03/20/2002 | EP1187813A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 03/20/2002 | EP1187637A2 Alpha or beta emitters attached to fragments in radioimmunotherapy |
| 03/20/2002 | EP1187634A1 Cell growth inhibition |
| 03/20/2002 | EP1187632A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/20/2002 | EP1187629A2 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 03/20/2002 | EP1187624A1 Conformationally constrained backbone cyclized interleukin-6 antagonists |
| 03/20/2002 | EP1187619A1 Anti-tumor agents comprising boroproline compounds |
| 03/20/2002 | EP1187613A1 Amide substituted imidazoquinolines |
| 03/20/2002 | EP1187592A2 Alpha v integrin receptor antagonists |
| 03/20/2002 | EP1143796A4 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| 03/20/2002 | EP1137415A4 Myt1 kinase inhibitors |
| 03/20/2002 | EP0944587B1 Metalloproteinase inhibitors |
| 03/20/2002 | EP0800829B1 Antitumor agent potentiator comprising il-6 antagonist |
| 03/20/2002 | EP0777680B1 Urokinase receptor ligands |
| 03/20/2002 | EP0731078B1 Terpene-quinone with antitumor activity |
| 03/20/2002 | EP0642351B1 New pharmaceutical uses of krill enzymes |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | CN1341117A 5-glycosyloxy-6-hydroxynaphtho [2,3-f] quinoline-7,12 dione having anticancer activities |
| 03/20/2002 | CN1341115A 16-halogen-epothilone derivatives, process for producing them and their pharmaceutical use |
| 03/20/2002 | CN1341114A C-21 Modified epothilones |
| 03/20/2002 | CN1341104A 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| 03/20/2002 | CN1341099A 2-aminopyridines containing fused ring substituents |
| 03/20/2002 | CN1341098A W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 03/20/2002 | CN1341029A Use of an OmpA enterobacteriumprotein associated with the ELAGIGILTV peptide for treating melanomas |
| 03/20/2002 | CN1341026A Small peptides and methods for treatment of asthma and inflammation |
| 03/20/2002 | CN1341025A Drugs containing sulfopyranosylacylglycerol derivatives |
| 03/20/2002 | CN1341020A Anti-tumor synergetic composition |
| 03/20/2002 | CN1341019A Antitumour synergistic composition |
| 03/20/2002 | CN1340361A Process for preparing xenomal or autogenous tumor vaccine of liposome |
| 03/20/2002 | CN1081187C Inhibitors of prenuyl transferases |
| 03/20/2002 | CN1081184C Fluorinated vitamin D3 analogs |
| 03/20/2002 | CN1081056C Anticarcinogen injection and its preparing process |
| 03/20/2002 | CN1081045C Anti-cancer medicine composition and its preparing method |
| 03/20/2002 | CN1081044C Medicine for treating cancer and preparing process thereof |
| 03/20/2002 | CN1081041C Medicine for treatment of malignant tumour and its prepn |
| 03/20/2002 | CN1081036C Anticarcinogen |
| 03/20/2002 | CN1081033C Partial slow-released glutathione inhibitor |
| 03/19/2002 | USRE37596 Hybridoma cell line which produces the monoclonal antibody bw sclc-1 having the deposit number ecacc no. 90022110. |
| 03/19/2002 | US6359181 Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
| 03/19/2002 | US6359154 Exceptional utility as antitumor agents; bioavailability and nontoxic; oral administration; e.g., 10-hydroxy-10-deacetyl baccatin iii; anticarcinogenic agents |
| 03/19/2002 | US6359145 Imidazole compounds |
| 03/19/2002 | US6359130 Bridged indenopyrrolocarbazoles |
| 03/19/2002 | US6359124 Nucleotide sequences for use in the diagnosis, detection and treatment of arrhythmia, long q-t syndrome and cancers |
| 03/19/2002 | US6359013 Styryl sulfone anticancer agents |